CLINICAL_TRIALS ClinicalTrials.gov record update

Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02069704
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:13.690841+00:00
Published At: 2019-07-23T00:00:00+00:00
Record Updated At: 2019-07-23
Results Posted At: 2019-07-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Colorectal Cancer (mCRC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-07-23"
protocolSection.identificationModule.nctId: "NCT02069704"
protocolSection.identificationModule.officialTitle: "Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN\u00ae), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-07-23"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.